SUBMISSION GUIDELINES

General Rules for Submission

• Abstracts must be submitted online via the CORA 2025 submission portal only (URL provided during the submission period). Abstracts submitted by email will not be considered.
• Presentation Type: Abstracts will be considered for oral presentation/poster discussion/poster viewing walk. The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.
• Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
• The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
• Presenting authors must be registered participants. Only accepted abstracts of presenting authors who have paid their registration fees by the announced presenters’ registration deadlines based on the submission type (regular or late-breaking) will be scheduled for presentation and included into the program.
• Abstracts must be submitted in English. All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission. Authors are advised to use either American English or British English spelling but not a mix of both.
• Abstracts must be original and include the most up-to-date data as of the time of submission. 
• Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Congress proceedings. All accepted abstracts of presenting authors who have completed their registrations by the announced deadlines for presenters will be published via the CORA 2025 website 2 weeks prior to the Congress. In case of any changes to the planned date, updated information will be posted here.
• Disclosure of Conflicts of Interest: At the time of submission, the submitting author will be requested to provide a brief conflict of interest statement on behalf of all co-authors. If the abstract is selected for oral presentation, the presenting author will be contacted additionally to complete a mandatory detailed Conflict of Interest Disclosure form.

Submission Requirements

Before you begin, please prepare the following information:

• Presenting author’s contact details:
  • Full first and family name(s)
  • Email address
  • Affiliation details: Institution/hospital, department, city, state (if relevant), country
• Author and co-authors’ details  (same details as for the presenting author)
• Preferred Presentation type: Oral/Poster Discussion/Poster Viewing Walk. ​
• Abstract title: Must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
• Abstract text: Limited to 250 words including acknowledgements. Please note: Word count is affected when tables are included.
• Abstract topic: Select the abstract topic per the list of topics.
• Images/Tables/Graphs: The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload up to 3 images/tables/graphs in JPG, GIF or PNG format.
• Abstracts should clearly state:
  • Background and aims
  • Methods
  • Results
  • Conclusions 
• Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
• Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
• Submissions may not contain patient names, hospital ID numbers or other identifying information.
• The submission form allows you to store your abstract as a DRAFT until the deadline. After the deadline if not submitted, drafts will be deleted.
• Click on the SUBMIT button at the end of the process in order to submit your abstract. You can make changes to your submitted abstract by the deadline. After the submission deadline abstracts cannot be modified or corrected.
• You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
• Please contact us if you have not received confirmation that your abstract has been submitted.
• Please do not submit multiple copies of the same abstract.

Abstract Submitters’ Declaration

• I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published as submitted.
• Submission of the abstract constitutes the consent of all authors to publication (e.g. congress website, program, other promotions, etc.)
• The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to the 8^th International Congress on Controversies in Rheumatology and Autoimmunity (CORA 205) and Kenes International Organizers of Congresses SA and its affiliates (together: the “Organizers“), nor the publication of any such Content by each of the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to privacy rights and/or intellectual property rights.
• The Abstract Submitter grants each of the Organizers the license and right to use, reproduce, publish, translate, distribute, and display the Content or any part thereof, in any manner and on any platform or media whatsoever, in each Organizer’s absolute discretion, on a royalty-free, perpetual, irrevocable nonexclusive basis.
• I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author (if different) may request to be copied on abstract correspondence.
  I understand that the presenting author must be a registered participant.
• The Organizers reserve the right to remove from publication and/or presentation an abstract that does not comply with the above.
• I understand that I must select a specific Theme and/or Topic for my abstract allocation. Although the Committee will work hard to honor this selection, this cannot be guaranteed. The Committee reserves the right to change the Theme and/or Topic under which the abstract was originally submitted.

Abstract Selection and Presentation

All submitted abstracts will be reviewed by the Scientific Committee. Consideration will be given to the author’s preference concerning poster or oral presentation. Submitting authors will be notified via email regarding the status of their abstract acceptance. The Committee’s decision is final.

• Oral presentation: The presenting author will be assigned a slot in a Free Communications session to present their work using PPT slides and take questions from the audience. The session will be held in a session hall onsite at a designated time.
• Poster discussion: The presenting author will be assigned a slot in a Poster Discussion session to present their work using an E-Poster and take questions from the audience. The session will be held in front of an E-Poster station onsite at a designated time.
• Poster viewing walk: Presenting authors will form groups and will view posters based on a certain topic accompanied by a Professor. Poster viewing walks will take place in the poster area onsite during breaks as specified in the program.

Further instructions for the relevant presentation type will be sent to presenting authors during the notification period and will be published on the CORA 2025 website under “Scientific Information”. Presentation formats may be changes by the organizers in which case presenting authors will be informed.